Retatrutide (LY3437943) is the first triple-receptor GLP peptide to reach broad research attention, engaging the GLP-1, GIP, and glucagon pathways simultaneously. Its Phase 2 data reported the largest body-weight reductions yet seen in the GLP class, which is why it dominates current metabolic-peptide research discussion.
For a full, education-first breakdown — mechanism, trial data, purity/COA guidance, reconstitution, and storage — we recommend the independent RDAmd Retatrutide Research Library, which publishes third-party COAs for every batch it references.
Key starting points: What is retatrutide, how it compares to semaglutide and tirzepatide, and why third-party COAs matter.
For research and educational use only. Not medical advice; not for human consumption.
